← All sarcoma trials
Opening soon—Ages 18 Years and up

Resistance Profiling Using Functional Imaging and Next Generation Sequencing in Refractory Gastrointestinal Stomal Tumors (GIST)

Sponsor: Universität Duisburg-Essen · NCT07109024 on ClinicalTrials.gov ↗

Bring this to your care team →

Conditions studied

Gastrointestinal Stromal Tumor (GIST)

What it tests

  • Generation of a comprehensive and single-lesion resistance profilediagnostic_test

Where it's running2 sites

2 international sites

  • University Hospital Essen

    Essen, Germany 45122

  • University Hospital Schleswig-Holstein, Dpt. of Hematlogy and Oncology

    Lübeck, Germany

See the official eligibility language

Shown exactly as written on ClinicalTrials.gov. Your oncologist is the right person to judge whether it fits your situation.

Inclusion Criteria:

* Advanced gastrointestinal stromal tumors history of exposure and progression or intolerance to imatinib, sunitinib, regorafenib and ripretinib
* Clinical indication for PET-CT and tumor biopsy (optional) (sarcoma center tumorboard protocol)
* Age 18 years and older
* FFPE tumor tissue available
* Previous imaging studies available (CT/MRI/PET Abdomen, ideally at baseline, best response and progression)
* ECOG ≤ 2
* Progressing tumor lesion(s) of which one is accessible for biopsy

Exclusion Criteria:

* contraindication for systemic TKI treatment
* contraindication for contrast-enhanced both CT and MRI imaging.
* GIST without KIT or PDGFRA mutations
* pregnant or breastfeeding women
* patient that - to the investigator's discretion - are not able or willing to comply with the provided protocol and visit schemes

Updated 2025-08-19 on ClinicalTrials.gov. Always confirm current details with the study team or your oncologist.